Related Experiment Video
Updated: May 16, 2026

Intramuscular Injections Along the Motor End Plates: A Minimally Invasive Approach to Shuttle Tracers Directly into Motor Neurons
Published on: July 13, 2015
Intramuscular Injection of rAAV2-retro for Low Motor Neuron Transduction: Evaluating Five Promoters
Xueqi Gong1,2, Haitong Gao1,2, Wenyuan Wang3,4
1Laboratory Animal Center, Fudan University, Shanghai 200032, China.
Recombinant adeno-associated viral vectors (rAAVs) efficiently deliver genes to lower motor neurons (LMNs) in the brainstem and spinal cord. The CAG and hCMV promoters showed the highest gene expression without causing toxicity, optimizing gene delivery for motor neuron diseases.
Area of Science:
- Neuroscience
- Molecular Biology
- Gene Therapy
Background:
- Recombinant adeno-associated viral vectors (rAAVs) are effective for transgene delivery to the nervous system.
- Promoter selection is crucial for transgene expression strength and cell-specificity.
- Previous studies show rAAV2-retro via intramuscular injection targets lower motor neurons (LMNs) in neonatal mice.
Purpose of the Study:
- To determine the optimal promoter for rAAV2-retro-mediated transgene expression in the central nervous system (CNS).
- To compare the efficacy of five common promoters: mPGK, CAG, hCMV, CBA, and hSyn.
- To assess the safety and cell-specificity of rAAV2-retro gene delivery to LMNs.
Main Methods:
- Intramuscular injection of rAAV2-retro vectors with different promoters into neonatal C57BL/6J mice.
- Utilized light-sheet illumination imaging and confocal microscopy to analyze gene expression.
- Identified transduced cell types and evaluated gene expression levels.
Main Results:
- rAAV2-retro primarily targeted the brainstem and spinal cord within the CNS.
- CAG and hCMV promoters demonstrated the highest gene expression levels.
- Nearly all transduced cells were identified as LMNs, with no observed hepatotoxicity.
Conclusions:
- CAG and hCMV are superior promoters for rAAV2-retro-mediated gene delivery to LMNs in the CNS.
- This study provides crucial data for optimizing gene delivery strategies for motor neuron diseases.
- rAAV2-retro gene delivery to LMNs is safe and effective, offering potential therapeutic applications.
Related Concept Videos
Drugs Acting on Autonomic Ganglia: Stimulants
Ganglionic stimulants activate NM nicotinic receptors in autonomic ganglia, falling into two categories: nicotine mimetics [e.g., lobeline, dimethylpiperazine, tetramethylammonium] and muscarinic receptor agonists [e.g., muscarine, methacholine]. The first category's action is rapid and blocked by nicotinic receptor antagonists, while the second category's action is delayed and blocked by atropine-like agents. Nicotine, an alkaloid, affects the heart rate by stimulating sympathetic or...
Classification of Skeletal Muscle Relaxants
Peripherally acting skeletal muscle relaxants interfere with the neurotransmission at the neuromuscular end plate to induce paralysis during...
Directly Acting Muscle Relaxants: Dantrolene and Botulinum Toxin
The binding of dantrolene to the RYR1...
Skeletal Muscle Relaxants: Therapeutic Uses
Peripherally and Centrally Acting Muscle Relaxants: A Comparison
Centrally acting muscle relaxants can be further divided into spasmolytic and antispasmodic drugs. Spasmolytic drugs,...
Centrally Acting Muscle Relaxants: Therapeutic Uses
Centrally acting drugs are classified into spasmolytic and antispasmodic drugs. Spasmolytic drugs such as baclofen, diazepam, and tizanidine inhibit spinal motor neurons and decrease muscle tone. Spasmolytic drugs are administered for severe and chronic spasms due to multiple sclerosis, cerebral palsy, stroke, and spinal cord and muscle injuries. However,...

